© 2012 The Japan Society of Histochemistry and Molecule targeting therapy using
somatostatin (SS) analogues has become a widely accepted modality to treat …

The treatment landscape and biologic understanding of neuroendocrine tumors (NET) has
shifted dramatically in recent years. Recent studies have shown that somatostatin analogues …

Objective Somatostatin receptors (SSTRs), products of gene superfamily SSTR1-5, are
commonly expressed in neuroendocrine tumors (NETs). Somatostatin analogs (SSAs) bind …

Neuroendocrine tumours (NETs) represent a heterogeneous family of neoplasms, which
may develop from different endocrine glands (such as the pituitary, the parathyroid or the …

Introduction 3. Molecular and biochemical characterization of SSTRs 4. Physiological roles
of SSTRs 5. SSTRs and tumor cell proliferation 5.1 Direct antiproliferative effects 5.1. 1 …

Simple Summary Immunolocalization of somatostatin receptor 2 (SSTR2) could predict the
therapeutic efficacy of somatostatin analogues (SSAs) in neuroendocrine tumors (NETs) …

Somatostatin is a peptide with a potent and broad antisecretory action, which makes it an
invaluable drug target for the pharmacological management of pituitary adenomas and …

Somatostatin analogs for the diagnosis and therapy of neuroendocrine tumors (NETs) have
been used in clinical applications for more than two decades. Five somatostatin receptor …

Background Somatostatin (SS) acts as a universal endocrine off-switch, and also inhibits the
growth of neuroendocrine tumours through its specific receptors (SSTRs). Somatostatin …

Well-differentiated neuroendocrine tumors (NT) expresses somatostatin receptors (sstr). A
composition of sstr subtype determines biological behavior. We therefore evaluated their …